Metagenomi Halts ALS Research Following Biogen and Ionis Setbacks

Metagenomi's Decision:
Metagenomi has decided to axe its amyotrophic lateral sclerosis (ALS) program due to setbacks observed in similar programs by competitors Biogen and Ionis.

Biogen and Ionis Setbacks:
Biogen halted its work on Ionis-partnered oligonucleotides for ALS and Angelman syndrome after disappointing clinical trial results.

Industry Challenges:
The pharmaceutical industry is facing challenges, with companies like Evotec planning layoffs due to a "challenging market".

Metagenomi's Strategy:
Metagenomi is seeking a partner for a program that Moderna dropped, indicating a strategic shift in its pipeline.

Impact on ALS Research:
The decision by Metagenomi and the setbacks faced by Biogen and Ionis may impact the overall progress in ALS research and treatment development.